Agenus (AGEN) to Release Earnings on Tuesday

Agenus (NASDAQ:AGEN) will announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($3.10) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to analyst estimates of $54.21 million. On average, analysts expect Agenus to post $-8 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Agenus Stock Performance

AGEN stock opened at $13.07 on Friday. The firm has a fifty day moving average price of $10.88 and a 200 day moving average price of $13.44. Agenus has a fifty-two week low of $4.78 and a fifty-two week high of $42.60. The firm has a market cap of $265.06 million, a PE ratio of -0.92 and a beta of 1.25.

Analyst Ratings Changes

AGEN has been the subject of a number of recent research reports. StockNews.com assumed coverage on shares of Agenus in a research note on Wednesday, April 17th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $160.00 price objective on shares of Agenus in a research note on Thursday, March 14th. Finally, B. Riley lowered their price objective on Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 18th.

Insiders Place Their Bets

In other Agenus news, insider Garo H. Armen bought 25,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were purchased at an average price of $13.00 per share, with a total value of $325,000.00. Following the completion of the purchase, the insider now owns 31,298 shares in the company, valued at approximately $406,874. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.80% of the stock is owned by insiders.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.